<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363438">
  <stage>Registered</stage>
  <submitdate>3/01/2013</submitdate>
  <approvaldate>11/01/2013</approvaldate>
  <actrnumber>ACTRN12613000032752</actrnumber>
  <trial_identification>
    <studytitle>Statin Therapy in Ischemia-Reperfusion Injury sustained during a heart attack</studytitle>
    <scientifictitle>Statin Therapy in Ischemia-Reperfusion Injury: A randomised trial to evaluate the effect of high dose rosuvastatin on myocardial infarct size post ST elevation myocardial infarction (STEMI). </scientifictitle>
    <utrn>U1111-1138-1887 </utrn>
    <trialacronym>STIR (STEMI)</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute ST Elevation Myocardial Infarction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rosuvastatin 40 mgs orally on randomisation and daily for 5 days post angioplasty. Angioplasty is performed as soon as  possible post randomisation.</interventions>
    <comparator>Placebo (Microcrystalline cellulose) tablet on randomisation and then rosuvastatin 20 mgs orally daily for 5 days with the first dose of drug commenced the next day after randomisation.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myocardial Infarction (MI) size will be assessed by Cardiac Magnetic Resonance (CMR) late gadolinium enhancement</outcome>
      <timepoint> One CMR performed at days 4-6 post MI</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural success as assessed by coronary angiographic flow indices including Thrombolysis In Myocardial Infarction (TIMI) flow grade, corrected TIMI frame count (cTFC), and myocardial blush grade (MBG) in the infarct-related artery and cTFC in the non-infarct related artery.</outcome>
      <timepoint>Baseline at the time of the angioplasty.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and magnitude of CMR defined microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH)</outcome>
      <timepoint>Assessed by CMR completed once at 4-6 days post MI</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of clinical events (death, MI, target vessel revasularization)</outcome>
      <timepoint>30 days post randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Symptoms of acute myocardial infarction within 12 hours with ST elevation of more than 1 mm in at least two contigous leads on ECG of new onset Left Bundle Branch Block.
Provision of written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Cardiogenic shock or symptomatic hypotension or sitting SBP &lt; 95 mm Hg
Previous MI
Standard CMR contraindications (e.g. pacemaker, severe claustrophobia etc.)
Known serious or hypersensitivity reactions to statin
known familial hypercholesterolemia
known active liver disease or significant renal failure (eGFR &lt; 45 mls/min)
Non-cardiac comorbidity with life expectation &lt; 1 year.
Patients who are Filipino, Chinese, Japanese, Korean or Vietnamese.
Patients taking any of the following cyclosporine, gemfibrozel or fusidic acid.
Attending consultant intends to use high dose statin therapy, Atorvastatin 80 mgs or Rosuvastatin 40 mgs.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/02/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>The Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>5001 - Adelaide</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>2065 - Royal North Shore Hospital</postcode>
    <postcode>2170 - Liverpool</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>SAHMRI</primarysponsorname>
    <primarysponsoraddress>Level 9, 121 King William Street, Po Box 11060,
Adelaide SA 5001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>South Australian Health and Medical Research Institute (SAHMRI)</fundingname>
      <fundingaddress>Level 9, 121 King William Street, Po Box 11060,
Adelaide SA 5001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to ascertain whether giving high doses of a cholesterol lowering drug (statin) can reduce the amount of damage caused to the heart by having a lack of oxygen and then having blood restored to the heart quickly when the blocked artery is opened by the insertion of a stent. Tissue damage may be caused when the supply of oxygen is restored to the heart. There are sound biological reasons but limited data that shows that by giving a high dose of a statin drug it is believed that the injury to the heart may be lessened and that incidences of heart failure caused by the heart attack may be lessened.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
The Flats G5  Rooms 3 and 4
Flinders Drive
Flinders Medical Centre, Bedford Park SA 5042
</ethicaddress>
      <ethicapprovaldate>19/12/2012</ethicapprovaldate>
      <hrec>EC00188</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Joseph Selvanayagam</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
Flinders Drive
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Christine Edwards</name>
      <address>SAHMRI
Mark Oliphant Building
Box 15, Laffer Drive
Science Park
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8201 5656</phone>
      <fax>+61 8 8201 7701</fax>
      <email>christine.edwards@sahmri.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Joseph Selvanayagam</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
Flinders Drive
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Christine Edwards</name>
      <address>SAHMRI
Mark Oliphant Building
Box 15, Laffer Drive
Science Park
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8201 5656</phone>
      <fax>+61 8 8201 7701</fax>
      <email>christine.edwards@sahmri.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>